nach oben

PharmacoEconomics

Erschienen in:

01.02.2004 | Correspondence

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature

verfasst von: Thomas Hammerschmidt, Kurt Banz, Stefan Wagenpfeil, Albrecht Neiss, Peter Wutzler

Erschienen in: PharmacoEconomics | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Excerpt

In a recent issue of PharmacoEconomics, Thiry et al.[1] provided a very detailed review of the literature on economic analyses of possible varicella vaccination programmes. Their review presents an extensive source of information for decision makers, especially concerning methods and data used in these evaluations. Although the results of the evaluations are presented in a very detailed matter, they appear to be not fully comprehensive. Based on our knowledge of the studies covered in the review and our own model-based analysis,[2] we would like to add to the review and provide arguments that possibly lead to different conclusions. …

Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38CrossRef

Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine varicella vaccination in Germany. Vaccine 2003; 21: 1256–67CrossRef

Wutzler P, Neiss A, Banz K, et al. Can varicella be eliminated by vaccination: potential clinical and economic effects of universal childhood vaccination in Germany. Med Microbiol Immunol 2002; 191: 89–96CrossRef

Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271: 375–81CrossRef

Huse DM, Meissner HC, Lacey MJ, et al. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994; 124: 869–874CrossRef

Galil K, Brown C, Lin F, et al. Hospitalization for varicella in the United States, 1988–1999. Pediatr Infect Dis 2002; 21: 931–4CrossRef

Hammerschmidt T, Banz K, Wagenpfeil S, et al. Universal varicella vaccination of children in the USA: implications for Germany. Infection 2003; 31 Suppl. 1: 161

Diez-Domingo JD, Ridoa M, Latour J, et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17: 1306–11CrossRef

Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142–51CrossRef

10.

Hope-Simpson RE. The nature of herpes-zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9–20PubMedPubMedCentral

11.

Seward JF, Jumaan AO, Galil K, et al. Varicella vaccine and shingles. JAMA 2002; 287: 2211–2CrossRef

12.

Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to immunity boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500–7CrossRef

13.

Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678–82CrossRef

Titel: Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature
verfasst von: Thomas Hammerschmidt
Kurt Banz
Stefan Wagenpfeil
Albrecht Neiss
Peter Wutzler
Publikationsdatum: 01.02.2004
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 2/2004
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200422020-00005

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2004

Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis

The Generation Gap

Cost of Stress Urinary Incontinence

Infliximab

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors’ Reply